ABSTRACT. Endothelium-derived relaxing factor (EDRF), believed to be nitric oxide or a compound that releases nitric oxide, has been previously identified in the pulmonary and systemic vasculature of the newborn guinea pig using isolated arterial rings. The aim of our study was to determine if EDRF regulates vasomotor tone a t the level of resistance vessels in the neonatal pulmonary circulation.
knowledge about the identity of EDRF, its biosynthesis, and its role in the control of vascular resistance in adult animals including the human. EDRF is now characterized as nitric oxide (2) (3) (4) or a nitrosothiol such as s-nitrosocysteine (5) . The dilator effect of EDRF in vitro and in vivo has been studied by inhibitors such as free Hb, which binds EDRF produced by the endothelium, and methylene blue, which blocks EDRF-induced cGMP production in adjacent smooth muscle (6, 7) . L-arginine is a putative precursor of EDRF, and recently an analog of arginine, NMA, was shown to specifically block EDRF production in vitro (8, 9) . In addition, NMA has been used in vivo in adult animals and humans to demonstrate an important role for EDRF in the control of resting systemic arterial pressure as well as mediation of changes in systemic vascular resistance by acetylcholine and other substances (I 0-12).
Little is known about the role of EDRF in the control of the perinatal circulation. A very recent report suggests that EDRF synthesis may contribute to the decrease of pulmonary vascular resistance that occurs at birth ( 13), but it is not known whether impaired EDRF activity is involved in the pulmonary hypertension associated with a variety of neonatal lung diseases, such as persistent pulmonary hypertension of the newborn and bronchopulmonary dysplasia. In previous work (14) , we demonstrated the presence of EDRF in isolated vascular rings from the pulmonary artery and descending aorta of the newborn guinea pig. One finding was that in vitro, bradykinin, a putative mediator of the pulmonary hernodynamic adjustments at birth (l5), relaxed the preconstricted neonatal pulmonary artery ring by an EDRFdependent mechanism. The purpose of our present study was to determine if EDRF plays a role in the neonatal pulmonary microvasculature as an important vasoactive substance involved in control of pulmonary vascular resistance.
MATERIALS AND METHODS
Isolated perjiused newborn guinea pig lung. Term (gestational age 65-67 d) Duncan-Hartley neonatal guinea pigs were used. Isolated lungs were studied from animals on the day of natural birth and up to 3 d old. The term newborn guinea pigs weighed 80-100 g and were anesthetized with 15 mg pentobarbital intraperitoneally. For experiments in which the cyclooxygenase pathway was blocked, indomethacin was administered using 5 mg/ kg intraperitoneally 30 min before dissection, and the indomethacin concentration in the perfusate was 0.5 pg/mL (1 3, 15).
After anesthesia, an endotracheal catheter was sutured into the trachea via a tracheostomy. The newborn guinea pig was ventilated with humidified room air (33°C) using a constant tidal volume to give a peak inspiratory pressure of 10 mm Hg. The ventilator rate was 6O/min and the positive end-expiratory pressure was 2 cm H 2 0 . After a midline thoracotomy, the ductus arteriosus was ligated. A polyvinyl catheter with distal and sideport openings was inserted through the right ventricle into the main pulmonary artery, where it was ligated in place. The lungs were perfused at 4 mL/min using a peristaltic pump. The perfusion system was nonrecirculating, using a 4% albumin KrebsHenseleit solution equilibrated with 21 % Oz, 5% C02, and 74% Nz at 38°C. The perfilsate pH was 7.37 t 0.01, Pcol was 4.8 k 0.3 kPa (36 + 2 torr) and Poz was 2 1.1 i 0.4 kPa ( 159 + 3 torr).
Lung effluent flowed out of a large left ventriculotomy. Together the heart and lungs were then carefully excised and suspended from the endotracheal tube in a humidified chamber warmed to 38°C by a water jacket. PAP and phasic airway pressures were continuously recorded.
Protocols,for assessing control of PAP by EDRF. The isolated lung was perfused for 10 min leading to a steady PAP baseline. Each lung was exposed to a series of pharmacologic agents in the perfusate. A concentrated stock of each pharmacologic agent was made in distilled water on the day of the experiment. Aliquots were added to a calibrated perfusate reservoir, thereby exposing the lung to continuous levels of one or more agents sequentially.
In pilot experiments, we examined the effect of angiotensin I1 on PAP. We defined a submaximal pressor dose that did not lead to irreversible changes in PAP associated with lung edema. Therefore, in our present study, PAP was increased submaxinially by at least 100%, using increasing concentrations of angiotensin 11, before adding bradykinin or L-arginine to the perfusate reservoir in an attempt to induce EDRF production and decrease PAP.
Five separate protocols were used to assess control of PAP by EDRF. The first protocol used Hb (10 pM), NMA (low dose, 100 pM), or both inhibitors (added in random order) mixed into the perfusate in an attempt to reverse bradykinin-induced vasodilation. In the second protocol, NMA alone at a higher dose (200 pM) was added to the perfusate during a reduction in PAP by bradykinin. This experiment was performed with and without indomethacin pretreatment (16) to determine to what extent vasodilator prostaglandins were responsible for the bradykinininduced vasodilation in this animal model. In the third protocol, the effect of NMA (200 pM) on baseline PAP and sequentially higher concentrations of angiotensin I1 (0, 3, 6, and 12 nM) was studied in control versus NMA-pretreated lungs. The lungs were treated with NMA for 10 min before measuring changes in baseline PAP or pressor responses to angiotensin 11. In the guinea pig, the increase in systemic arterial pressure after an injection of NMA is well established in several minutes and remains persistently elevated for over 20 min (17) . In the fourth protocol, the effect of NMA pretreatment (10 min) on the bradykinininduced decrease in PAP was determined using sequential increases in bradykinin concentration (0.1 to 10 nM). Based on results from protocol 3, the NMA-pretreated lungs were perfused with a solution containing 25% of the angiotensin I1 concentration used in control lungs so that an equal pressor response was established in both groups before bradykinin-induced vasodilation was attempted. The fifth protocol tested the effect of Larginine (2 nM, precursor of EDRF) on the angiotensin IIinduced elevation of PAP.
Materials. Standard Krebs-Henseleit solution contains 1 18 mM NaC1, 25 mM NaHCO?, 4.7 mM KCI, 2.5 mM CaCl2, 1.2 mM MgC12, 1.1 mM NaH2P04, and 1 1.1 mM dextrose. Angiotensin 11, bradykinin, papaverine, indomethacin, methemoglobin, and L-arginine were obtained from Sigma Chemical Company (St. Louis, MO). NMA was obtained from Calbiochem (San Diego, CA). All drugs were dissolved in deionized water. Fresh indomethacin was made as a 10 mM solution with 100 mM NaHCOI. Hb was prepared from bovine-methemoglobin by combining the latter with a 10-fold molar excess of sodium dithionite and dialyzing this mixture against distilled water (6) . The pH, Pco2, and PO, of the albumin-containing, Krebs-Henseleit solution was not changed by the addition of the drugs listed above.
Statistical analysis. One-way analysis of variance followed by paired t tests using the Bonferroni correction (for multiple serial tests with each perfusion) was performed with one exception (18) . The principal endpoints were the change in PAP caused by sequential pharmacologic interventions. A two-way analysis of variance, followed by unpaired t tests (with correction), was used for the protocol examining the effect of NMA-pretreatment on the dose-related, bradykinin-induced decrease in PAP. Statistical significance was defined as p < 0.05. All values are reported as mean + SEM.
RESULTS
Baseline mean perfusion pressure was 0.9 f 0.05 kPa (7.0 i 0.4 torr) and it increased by only 0.13 kPa (1 torr) after 40 min of perfusion with the 4% albumin Krebs-Henseleit solution alone.
Protocol I. Efict of llb, low dose NMA, or both on bradykinininduced decrease in PAP. The results from this protocol are shown in Figure I . A submaximal increase in PAP to 182 i 32% above baseline was first achieved with angiotensin 11, which was continuously perfused into the lung. Bradykinin (10 nM) reduced the angiotensin 11-induced elevation in PAP to 33 i 9% above baseline. In preliminary studies, we found that while the lung was continuously exposed to bradykinin the reduction in PAP remained steady. The EDRF inhibitors, Hb (10 pM) or NMA (100 pM), partially reversed the bradykinin-induced reduction in PAP to 77 + 5 and 94 5 24% above baseline, respectively, over a 10-min period. When the EDRF inhibitor that was not initially used was added to the perfusate (exposing the lung to both inhibitors), a rapid reversal of the bradykinin-induced reduction in PAP to 246 + 25% of baseline occurred in 2 to 3 min. This elevation in PAP was similar to the level initially achieved with angiotensin I1 alone. Figure 2 demonstrates a polygraph recording of PAP during this protocol; in addition, this lung was pretreated with indomethacin. A submaximal pressor response, 188% above baseline, was achieved with 225 nM angiotensin 11. Increasing the perfusate concentration of bradykinin resulted in serial step-like decreases in PAP to 29% above baseline for 10 nM bradykinin. With both angiotensin I1 and bradykinin remaining in the perfusate for the duration of the experiment, NMA (200 pM) resulted in a gradual rise in PAP over 10 min and the PAP was greater than that observed with angiotensin I1 alone. Next, addition of L-arginine (2 mM) promptly reversed the effect of NMA. Figure 3 Fig. 2 . Polygraph tracing of PAP from the isolated, perfused lung of the newborn guinea pig (pretreated with indomethacin) demonstrating the effect of NMA (200 pM), an inhibitor of EDRF production, on bradykinin-induced vasodilation. First, baseline PAP was elevated by angiotensin 11. NMA was administered after bradykinin, and the effect of NMA was reversed by L-arginine. Fig. 3 . Effect of NMA (200 pM) on the bradykinin-induced decrease in PAP of the isolated, perfused, newborn guinea pig lung. First, baseline PAP was elevated by angiotensin 11. NMA, an inhibitor of EDRF production was administered after bradykinin, and the effect of NMA could be reversed by L-arginine. pretreated with indomethacin gave similar results (Fig. 2 shows  example) . Indomethacin did not attenuate the vasodilator effect of bradykinin (10 nM) on the elevation of PAP induced by angiotensin 11; bradykinin reduced PAP by 88 ? 1 % (control 84
Protocol 2. Ejfkct of high-dose NMA alone afier bradykinininduced decrease in PAP.
Protocol 3. EffEct of NMA pretreatment on baseline PAP and PAP response to angiotensin 11. The results from these experiments are shown in Figure 4 . PAP rose 46 + 13% from baseline to a new steady state within 10 min after adding NMA (200 pM) alone to the perfusate. For two submaximal doses of angiotensin I1 (3 and 6 nM), the PAP pressor response was greater in the NMA-pretreated groups compared to control. For the 6-nM angiotensin I1 dose, the pressor response for the NMA-pretreated lungs (306 k 65%) was greater than would be expected by the effect of NMA on baseline PAP (46 5 13%) plus the effect of angiotensin I1 alone (133 f 49%, 6 nM control).
Protocol 4. Effect of NMA pretreatment on braclykinin-induced decrease in PAP. Figure 5 demonstrates the results from these studies. Because NMA pretreatment increases baseline PAP and vasoreactivity to angiotensin 11, a lower dose of angiotensin I1 ( 15 nM versus 60 nM) was used to get a similar pressor response in NMA and control groups, respectively, before attempting to decrease PAP. In the NMA pretreatment and control groups, the pressor response to angiotensin I1 was 250 f 55 and 194 f 4 1 % above baseline PAP, respectively (results not significantly different). NMA significantly attenuated the decrease in PAP using bradykinin concentrations of 0.1, 0.5, and 1 . O nM, but there was related decrease in PAP of the isolated, perfused, newborn guinea pig lung. Each treated lung was exposed to NMA (an inhibitor of EDRF production) for at least 10 min before exposure to angiotensin 11. Levels of angiotensin 11, 15 and 60 nM, for NMA-pretreated and control lungs, respectively, were used to give an equal pressor response before administration of incremental doses of bradykinin.
no difference compared to the control group at 10 nM, which gives a near maximal response. Figure 6 demonstrates a polygraph tracing from an experiment using this protocol. L-arginine (2 mM), the same concentratioil used to reverse NMA, was found to rapidly and appreciably reduce the angiotensin 11-induced elevation in PAP. from the pulmonary artery and descending aorta of 1-to 3-d-old guinea pigs. The dilator action of bradykinin on pulmonary artery rings in vitro was attributed primarily to EDRF (14) . In the present study, we examined whether EDRF plays an important role in the neonatal lung microvasculature as a vasoactive substance that controls neonatal pulmonary vascular resistance. Results of this work using the isolated perfused newborn guinea pig lung indicate that EDRF is involved in: 1) the control of baseline pulmonary vascular tone; 2) the vasoreactivity of angiotensin 11; and 3) the mediation, in part, of the dilator action of bradykinin. Using acetylcholine as a stimulus for EDRF production, there is evidence that EDRF is involved in the control of pulmonary vascular resistance in the adult rabbit (19). Except for one recent report indicating that EDRF may play a role in the pulmonary hemodynamic adjustments at birth in lambs (I 3), there are no studies in other newborn species showing a role for EDRF in circulatory control under physiologic conditions or in lung injury.
Protocol 5. Effect of L-arginine on angiotensin 11-induced elevation of PAP.
Angiotensin I1 was selected as the vasoconstricting substance used to raise pulmonary vascular resistance in all our experiments before attempting vasodilation with bradykinin. Angiotensin I1 was selected for several reasons: I ) it is elevated in the human at birth (20); 2) the time course of change in the elevated levels of angiotensin I1 at birth and the effect of angiotensin I1 on the circulatory adjustments at birth in the unanesthetized newborn lamb have been described (21); and 3) pilot studies using submaximal concentrations of angiotensin 11 infused continuously into the isolated newborn guinea pig lung gave a stable elevation in PAP with reversibility and no overt edema. Preliminary studies ~i t h continuous infusions of the thromboxane analog, U-466 19, 1s the vasoconstricting agent were not successful in our model 2ecause of observable edema production. Bradykinin was chosen .o induce EDRF production because: I ) our previous experience n isolated rings indicated that bradykinin stimulated EDRF xoduction; and 2) BK is a putative mediator of the circulatory idjustments at birth, particularly the decrease in pulmonary ~ascular resistance (1 5).
Using the first experimental protocol, we found that after a iubmaximal elevation in PAP by angiotensin 11, subsequent lasodilator actions of bradykinin (10 nM) could be partially .eversed by two known inhibitors of EDRF, Hb and NMA. Hb )inds EDRF produced by the endothelial cell, thereby limiting ts access to smooth muscle (6) . NMA, an analog of L-arginine, ias been shown to inhibit EDRF production (8, 9) . After the lecrease in PAP induced by bradykinin, when H b and NMA vere added in random order to the perfusate reservoir, a com-)lete reversal of bradykinin's vasodilator action was observed. The use of two EDRF inhibitors, structurally different and with lifferent modes of action, indirectly demonstrates that EDRF Las a major role in the control of pulmonary vascular resistance n our model. Based on the second protocol, we found that a ligher dose of NMA achieved the same effect on PAP as Hb and (MA together in the first experiments.
In the third protocol, we used NMA to assess the role of EDRF on baseline PAP and the PAP response to angiotensin 11. NMA raised baseline PAP, suggesting that EDRF is being continuously produced in the isolated perfused lung of the newborn guinea pig. This finding is not surprising considering the work of other investigators who have administered NMA to intact adult animals, resulting in appreciabie elevations in systemic arterial pressure (10, 1 I). In our present study, NMA also increased the PAP response to angiotensin 11, and this could not be explained by the increase in baseline PAP alone. Therefore. these results indicate that vasoreactivity to angiotensin I1 had increased. The increase in baseline PAP and the increase in vasoreactivity to angiotensin I1 caused by NMA explain to a large extent how the bradykinin-induced decrease in PAP (from protocol 1 and 2) could be reversed. The implication from these findings extended to the intact newborn animal is that pulmonary EDRF production serves as a counterbalancing mechanism to keep pulmonary vascular resistance low at birth, in the face of potent circulating vasoconstrictor substances such as angiotensin I1 and norepinephrine (2 1, 22).
In the fourth protocol, we determined whether the bradykinininduced vasodilation that was observed in earlier experiments could be mediated by EDRF or the cyclooxygenase pathway. Bradykinin is a known stimulus for endothelial production of prostacyclin (23). However, in our present study, indomethacin did not block the dilator effect of bradykinin on the elevated PAP caused by angiotensin 11. In the chronically instrumented fetal lamb preparation, previous work has shown that only a minor portion of bradykinin's vasodilator action on the pulmonary circulation is mediated via the cyclooxygenase pathway (24) . Furthermore, cyclooxygenase blockade leading to inhibition of prostacyclin production resulted in only small elevations of pulmonary artery pressure in the spontaneously breathing, unanesthetized lamb at birth (25). In contrast, in our present study we found that submaximal vasodilation by bradykinin could be markedly attenuated by NMA. If future studies using specific assays confirm that bradykinin does play a role in the perinatal pulmonary hemodynamic adjustments (15), then bradykinininduced EDRF production may be an important interaction at birth.
In each of our studies using NMA, we found that the elevation in PAP that resulted from this treatment could be reversed by 1.-arginine and papaverine. These findings indicate that NMA did not irreversibly damage the lung, resulting in an elevation of PAP caused by edema. In addition, these findings suggest that NMA was blocking EDRF production via a mechanism involving the metabolism of L-arginine.
We also found that L-arginine itself, in the absence of NMA, could lower PAP, which had been elevated by angiotensin 11. The appreciable decrease in vascular tone induced by L-arginine in this experiment was somewhat unexpected based on other reports in the literature. Using isolated pulmonary artery rings from the adult rat, L-arginine (3.2 X lo-' M) did not reverse norepinephrine-induced contractions (26) . The same investigators, using the isolated perfused rat lung, demonstrated that a bolus injection of L-arginine could reverse hypoxic pulmonary vasoconstriction. In work by others, L-arginine produced only small but significant endothelium-dependent relaxations in rabbit aortic rings that had been preconstricted with phenylephrine (9) . In isolated rings from bovine pulmonary arteries preconstricted with phenylephrine, L-arginine did not decrease tone unless the rings were first made refractory to endotheliumdependent relaxation by calcium ionophore A23187 (27). In contrast, a report (28) has recently noted that an infusion of Larginine reduces systemic blood pressure in normotensive volunteers and patients with essential hypertension. The latter report is consistent with our findings in the isolated, newborn guinea pig lung, where L-arginine may be a substrate-limiting factor for EDRF production.
In summary, our present study provided evidence that EDRF is present in the microvasculature of a term, neonatal animal by the neonatal lung may be involved in the pathogenesis of Am J Physiol259:H 1 9 2 1 -~1 9 2 7 pulmonary hypertensive disorders of the newborn.
